Freenome’s Breakthrough and Alamar’s Automation Push the Next Phase of Multiomics

Regulatory wins and automated workflows are making multiomics practical for serial screening, neuro testing, and longitudinal care.

Updated

What is this trend?

FDA momentum and automated plasma workflows are turning multiomics from promising biomarker science into repeatable, clinically deployable testing for screening, neurodegeneration, and surveillance.

  • FDA designations and clearances are validating blood-based diagnostics for real care pathways.
  • Automation is the next moat: low-volume, high-throughput workflows enable serial testing at scale.
  • Neuro biomarker panels are expanding from research tools into operational Alzheimer’s and cognitive decline use cases.
  • Value is shifting toward longitudinal data, reimbursement, and workflow integration—not single-test performance.
  • Platforms that combine analytics, automation, and regulatory progress are best positioned to win.

What’s the latest?

On August 12, the FDA granted Freenome’s SimpleScreen Lung Breakthrough Device Designation, while Zepto Life secured a major liquid biopsy grant, reinforcing that blood-based diagnostics are advancing

How it developed

  1. Infrastructure wins in diagnostics, AI embeds in workflows, and serial testing drives oncology revenue
    • Serial Blood Testing Is Becoming the Economic Engine in Oncology
  2. Workflow-specific AI clears first, companion diagnostics gain reimbursed access, and multiomics shifts to deployment
    • Freenome’s Breakthrough and Alamar’s Automation Push the Next Phase of Multiomics

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Related trends

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.